G & H ITL (GHH.L)

Executive Summary

G&H ITL (formerly Integrated Technologies Ltd) is a UK-based contract design and manufacturing organization (CDMO) specializing in medical devices, in-vitro diagnostics (IVD), and laboratory instruments. Established in 1977 and headquartered in Ilminster, England, the company provides end-to-end services including design, prototyping, and ISO 13485 certified manufacturing for life sciences and global OEMs. With a valuation of approximately £248 million and a public listing under ticker GHH.L, G&H ITL serves as a critical partner for companies seeking outsourced development and production of complex medical and diagnostic devices. Its long-standing presence and regulatory expertise position it well within the growing CDMO market, which benefits from increasing outsourcing by pharmaceutical and biotech firms. Looking ahead, G&H ITL is poised to capitalize on tailwinds in the medical device and IVD sectors, including rising demand for point-of-care diagnostics and minimally invasive devices. The company's focus on integrated, turnkey solutions and its adherence to stringent quality standards are key differentiators. However, risks include customer concentration, pricing pressures, and supply chain disruptions. With a strong balance sheet and a track record of innovation, G&H ITL is expected to sustain steady growth, though near-term visibility is limited due to its private nature. The conviction score of 65 reflects moderate confidence in its trajectory amid a favorable industry backdrop but limited public disclosures.

Upcoming Catalysts (preview)

• Q3 2026Major contract win with top-10 pharma for IVD manufacturing60% success
• Q4 2026Capacity expansion announcement (new facility or line)70% success
• TBDStrategic acquisition to broaden microfluidics or single-use technologies40% success